Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Laurus Labs Ltd. Share Price
Day's Range
Low
₹2,020.00
High
₹2,055.30
Price Summary
| Previous Close | ₹2,026.20 |
|---|---|
| Day's Range | ₹2,020.00 - ₹2,055.30 |
| Open | ₹2,021.10 |
| 52 Week Range | ₹823.10 - ₹2,037.20 |
| Volume | 13,88,039 |
| Market Cap | ₹0.11 |
| Previous Close | ₹2,026.25 |
|---|---|
| Day's Range | ₹2,020.10 - ₹2,054.55 |
| Open | ₹2,020.10 |
| 52 Week Range | ₹822.85 - ₹2,037.45 |
| Volume | 75,850 |
| Market Cap | ₹0.11 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 28,124.45 |
|---|---|
| Market Cap (₹ in Mn) | 0.11 |
| Dividend Yield(%) | 0.10 |
| Price/Earning (TTM) | 100.13 |
| TTM EPS (₹) | 20.24 |
| P/E Ratio | 60.25 |
| Book Value(₹) | 19.41 |
| PAT Margin (%) | 13.06 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 18.20 |
| Trade Value ( ₹ in Lacs) | 1,536.91 |
|---|---|
| Market Cap (₹ in Mn) | 0.11 |
| Dividend Yield(%) | 0.10 |
| Price/Earning (TTM) | 100.13 |
| TTM EPS (₹) | 20.24 |
| P/E Ratio | 60.25 |
| Book Value(₹) | 19.41 |
| PAT Margin (%) | 13.06 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 18.20 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 14327.5 | 55539.6 |
| Expenses | N/A | N/A |
| PBT | 2114.4 | 4882.2 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 1579.4 | 3583.4 |
About Laurus Labs Ltd.
| Founded | 2005 |
|---|---|
| NSE Symbol | LAURUSLABS |
Latest News
Laurus Labs submits analyst meet intimation
Samrat Pharmachem informs about scrutinizers report and voting results
Samrat Pharmachem has informed that the Scrutinizers Consolidated Report for remote e-voting and e-voting at the 34th Annual General Meeting held on Wednesday, September 23, 2026 at 01.00 PM IST via Video Conferencing (‘VC’) / Other Audio-Visual Means (‘OAVM’) is enclosed as ‘Annexure A’ along with Voting Results as ‘Annexure B’. Based on the consolidated Report of the Scrutinizer, all Resolutions as set out in the Notice of 34th Annual General Meeting has been duly approved by the Shareholders with requisite majority.
The above information is a part of company’s filings submitted to BSE.
Molbio Diagnostics informs about SAST
Kaya informs about closure of trading window
Pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, and the Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders of the Company, Kaya has informed that the trading window for dealing in the securities of the Company shall remain closed for all Designated Persons and their immediate relatives with effect from Thursday, October 1, 2026 till 48 hours after the declaration of the Unaudited Financial Results of the Company for the quarter and half year ending September 30, 2026. The date of the Board Meeting to consider the Unaudited Financial Results for the quarter & half year ending September 30, 2026, will be intimated in due course.
The above information is a part of company’s filings submitted to BSE.
Transpact Enterprises informs about closure of trading window
Pursuant to the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended, and the Company’s Code for Prohibition of Insider Trading, Transpact Enterprises has informed that the Trading Window for trading/ dealing in the securities of the Company shall remain closed for all Designated Persons and their Immediate Relatives with effect from Thursday, October 1, 2026 and shall remain closed until 48 hours after the declaration of the Financial Results of the Company for the half year ended September 30, 2026. The date of Board Meeting to consider and approve the Financial Results of the Company for the half year ended September 30, 2026 shall be intimated in due course.
The above information is a part of company’s filings submitted to BSE.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Laurus Labs Ltd. is ₹2,026.20 as of 2026-09-24.
The market capitalisation of Laurus Labs Ltd. is ₹109,480.76 as of 2026-09-24.
The 1-year return of Laurus Labs Ltd. is 1,116.15% as of 2026-09-24.
The P/E ratio of Laurus Labs Ltd. is 60.25 as of 2026-09-24.
The 52-week high and low of Laurus Labs Ltd. are ₹2,037.20 and ₹823.10, respectively, as of 2026-09-24.
People Also Ask
Laurus Labs Ltd. provides active pharmaceutical ingredients, generic formulations and contract‑development/manufacturing services, with strengths in antivirals, oncology and chronic therapies.
Laurus Labs Ltd. collaborates via API and formulation supply agreements and CDMO partnerships with global generic and branded pharma companies that serve hospitals worldwide.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
